Transgenomic, Inc. Launches Breakthrough Blood-Based Cancer Gene Testing Technology at 2012 American Society of Clinical Oncology Annual Meeting

Published: Jun 05, 2012

OMAHA, Neb.--(BUSINESS WIRE)--Transgenomic, Inc. (OTCBB: TBIO) today announced the commercial launch of its ICE COLD-PCR mutation detection technology, a breakthrough technology enabling unmatched sensitivity and complete DNA mutation detection using the standard sequencing equipment already installed in laboratories around the world. The launch coincides with the 2012 annual meeting of the American Society of Clinical Oncology.

Back to news